EPO and Alzheimer disease: We therefore propose that development of brain penetrating PHD inhibitors, with and without additional activity versus FIH (which contributes to regulation of the set of HIF target genes), is pursued with a view to investigating their potential for AD treatment, via alteration of synaptic function in the hippocampus, either mediated via EPO upregulation or not.